About: Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia. Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1, a multi-component prophylactic vaccine targeting skin and soft tissue infections with S. aureus bacteria; EVX-B2 to target multi-component prophylactic vaccine against gonorrhea bacteria; EVX-B3 to target bacterial pathogen associated with repeated infections; and EVX-V1, a multi-component prophylactic vaccine candidate for cytomegalovirus. The company was formerly known as Evaxion Biotech A/S and changed its name to Evaxion A/S in May 2025. Evaxion A/S was incorporated in 2008 and is based in Horsholm, Denmark.
Sector: Healthcare
Industry: Biotechnology
Latest price: $3.08 (-0.96%)
EVAX NASDAQ Evaxion Biotech AS
Evaxion Biotech AS share price
Atividade de preço de EVAX
Último preço
$ 3,080
Variação (24h)
-0,03 USD (0,96%)
Volume
38.27K
Volume (média 4 sem.)
-
Abertura
$ 3,10
Variação do dia
$ 3,00 - $ 3,17
Fechamento anterior
$ 3,11
Último negócio
29 Oct, 8:21 pm GMT+0
Atrasado
29 Oct, 8:21 pm GMT+0
EVAX price performance
Atrasado
29 Oct, 8:21 pm GMT+0
quote.marketSignals